within Pharmacolibrary.Drugs.ATC.C;

model C08CA16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0020166666666666666,
    adminDuration  = 600,
    adminMass      = 0.004,
    adminCount     = 1,
    Vd             = 0.00017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Clevidipine is an ultrashort-acting dihydropyridine calcium channel blocker used for the rapid reduction of blood pressure in cases of acute hypertension. It is administered intravenously and is approved for use in clinical settings such as perioperative hypertension and hypertensive emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following intravenous infusion.</p><h4>References</h4><ol><li>Ying Zhou, Xiao-Meng He, Hu-Qun Li, Yang Ni, Ming-Zhen Xu, Hui Chen, Wei-Yong Li,Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats.,Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,2014<a href='https://pubmed.ncbi.nlm.nih.gov/25480581/'>https://pubmed.ncbi.nlm.nih.gov/25480581/</a></li><li>Yan Wang, Lanting Zhao, Tengfei Li, Wen Yang, Qian Li, Luning Sun, Li Ding,Pharmacokinetics and tissue distribution study of clevidipine and its primary metabolite H152/81 in rats.,Biomedical chromatography : BMC,2018<a href='https://pubmed.ncbi.nlm.nih.gov/28707762/'>https://pubmed.ncbi.nlm.nih.gov/28707762/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08CA16;
